Involvement of c-Jun N-terminal kinase activities in skeletal muscle differentiation

Journal of Muscle Research and Cell Motility

Volumn 25, Issue 8, 2004, Pages 645-655

  Khurana, Ashwani ^a,b   Dey, Chinmoy S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CREATINE KINASE; MYOGENIN; MYOSIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOLIPID ANTIBODY; PROTEIN C JUN; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MOLECULAR PROBE; MUSCLE CELL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CREATINE KINASE; ENZYME ACTIVATION; IN SITU NICK-END LABELING; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SKELETAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17644400498     PISSN: 01424319     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10974-004-7099-1     Document Type: Article

References (31)

1. Adams V, Gielen S, Hambrecht R and Schuler G (2001) Apoptosis in skeletal muscle. Front Biosci 6: D1-D11.
2. Bengal E, Ransone L, Scharfmann, Dwarki VJ, Tapscott SJ, Weintraub H and Verma IM (1992) Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell 68: 507-519.
3. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM and Anderson DW (2001) SP600125, an anthra-xpyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98: 13681-13686.
4. Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and independent mechanisms. J Biol Chem 286: 1358-1362.
5. Caetano MS, Vieira-De-Abreu A, Teixeira LK, Werneck MB, Barcinski MA and Viola JP (2002) NFATC2 transcription factor regulates cell cycle progression during lymphocyte activation: evidence of its involvement in the control of cyclin gene expression. FASEB J 14: 1940-1942.
6. Cavigeli M, Dolfi F, Claret FX and Karin M (1995) Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14: 5957-5764.
7. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM and Glembotski CC (2000) p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 275: 23814-23824.
8. Cuenda A and Cohen, P (1999) Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem 274: 4341-4346.
9. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
10. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL and Chambers TC (2004) Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem. 279: 11957-11966.
11. Eferl R, Sibilia M, Hilberg F, Fuchsbichler A, Kufferath I, Guertl B, Zenz R, Wagner EF and Zatloukal, K (1999) Functions of c-Jun in liver and heart development. J Cell Biol 145: 1049-1061.
12. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K and Rotwein, PS (1991) "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J Biol Chem 266: 15917-15923.
13. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN and Ronai, Z (1998b) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12: 2658-2663.
14. Fuchs SY, Adler V, Pincus MR and Ronai Z (1998a) MEKK/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA. 95: 2586-2591.
15. Gredinger E, Gerber AN, Tamir Y, Tapscott SJ and Bengal E (1998) Mitogen activated protein kinase pathway is involved in the differentiation of muscle cells. J Biol Chem 273: 10436-10444.
16. Huynh H (2002) Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 20: 1297-1303.
17. Ichijo H (1999) From receptors to stress-activated MAP kinases. Oncogene 18: 6087-6093.
18. Khurana A and Dey CS (2002) Subtype specific roles of mitogen activated protein kinases in L6E9 skeletal muscle cell differentiation. Mol Cell Biochem 238: 27-39.
19. Liu ZG, Baskaran R, Lea-Chou ET, Wood LD, Chen Y, Karin M and Wang JYJ (1996a) Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384: 273-276.
20. Liu ZG, Hsu H, Goddel DV and Karin M (1996b) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87: 565-576.
21. Mc Gee MM, Campiani G, Ramunno A, Nacci V, Lawler M, Williams DC and Zisterer DM (2002) Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 277: 18383-18389.
22. Mosman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
23. Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C and Levrero M (1997) Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 275: 200-203.
24. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA and Holbrook NJ (2000) Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 20: 1713-1722.
25. Reinhard C, Shamoon B, Shyamala V and Williams LT (1997) Tumor necrosis factor alpha-induced activation of c-Jun N-terminal kinase is mediated by TRAF2. EMBO J 16: 1080-1092.
26. Roulston A, Reinhard C, Amiri P and Williams LT (1998) Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 273: 10232-10239.
27. Ryan KM, Phillips AC and Vousden KH (2001) Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 13: 332-337.
28. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M and Wagner EF (1999) Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech. Dev 9: 115-124.
29. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
30. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ, Rakic P and Flavell RA (1997) Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389: 865-870.
31. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C and Sal GD (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.